Chronomics secures £1.1m funding led by Anthemis and SOSV

Funding | Healthcare | South East | Technology

Chronomics has successfully secured more than £1.12m in funding, including significant investment from venture capital firm Anthemis, and follow on funding from SOSV, one of the world’s most active early-stage biotech investors.

The four founders of Chronomics are leading in their respective fields. Dr Tom Stubbs and Daniel Herranz worked at the forefront of epigenetics research at the University of Cambridge, where they collaborated with Dr Toby Call, a Bioenergy and Industrial Biotechnology expert, to define the first models.

The team brought on board Charles Ball whose extensive commercial experience has helped to explain the intricacies of epigenetic science to the public.

Chronomics seeks to revolutionise attitudes towards health management, from a generalist and reactive approach, to one that is personalised and proactive. Through a unique epigenetic saliva test, Chronomics profiles specific lifestyle and environmental indicators to provide accurate insights into a person’s health – such as their biological age, metabolic status, and the impact of smoke exposure on the body.

Chronomics has secured investment from two world-leading venture capital firms. SOSV invested in Chronomics through the RebelBio programme after reviewing 350 companies. Chronomics has since received follow on investment from SOSV. Anthemis, a venture investment and advisory firm dedicated to cultivating change in financial services, has provided Chronomics with significant investment.

Chronomics also secured funding from angel investors, including Laurence Garrett, senior partner with Highland Europe. Garrett was previously on the board of BlueGnome Ltd., a pioneer in gene testing to improve IVF success rate. Laurence has significant experience as a private investor in AI and deep tech companies, such as Speechmatics and FeatureSpace.

To have received backing from such eminent investors at such an early stage reflects their confidence in Chronomics’ proposition to bring advanced epigenetic testing into the mainstream. The company’s success in securing competitive funding will enable Chronomics to continue to harness the increased demand for personalised health management, as they continue to forge a company that is pioneering in its field.

CEO and Founder Dr Tom Stubbs said: “Reaching £1.12 in seed funding is a momentous milestone for Chronomics, having just launched the company last year. Receiving the support of prominent backers reflects their confidence in our company, and our vision of a future of personalised and proactive health management.”

Did you enjoy reading this content?  To get more great content like this subscribe to our magazine

Reader's Comments

Comments related to the current article

Leave a comment

Your email address will not be published. Required fields are marked *